The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GnRH Agonist Market Research Report 2024
Synopsis
GnRH, also known as gonadotropin-releasing hormone, is a peptide hormone secreted by the hypothalamus, which further stimulates the pituitary gland to release and synthesize gonadotropins, including follicle-stimulating hormone and luteinizing hormone. Controls the function of the ovary and the function of the testis. GnRH agonists are generally referred to as gonadotropin-releasing hormone agonists. Gonadorelin-releasing hormone agonists generally include triptorelin acetate injection, gonadorelin for injection, leuprolide acetate microspheres for injection and other drugs.
Global GnRH Agonist market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GnRH Agonist market research.
Key manufacturers engaged in the GnRH Agonist industry include Pfizer, AbbVie, AstraZeneca, Ferring, TerSera Therapeutics, Astellas Pharma, Takeda, LIVZON and Ipsen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GnRH Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GnRH Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GnRH Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
AbbVie
AstraZeneca
Ferring
TerSera Therapeutics
Astellas Pharma
Takeda
LIVZON
Ipsen
Sanofi
Endo
Tocris Bioscience
Sigma-Aldrich
MedChem Express
Arbor Pharmaceuticals
Segment by Type
Prostap
Zoladex
Triptorelin
Histrelin
Nafarelin
Others
Segment by Application
For Human
For Veterinary
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GnRH Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
GnRH, also known as gonadotropin-releasing hormone, is a peptide hormone secreted by the hypothalamus, which further stimulates the pituitary gland to release and synthesize gonadotropins, including follicle-stimulating hormone and luteinizing hormone. Controls the function of the ovary and the function of the testis. GnRH agonists are generally referred to as gonadotropin-releasing hormone agonists. Gonadorelin-releasing hormone agonists generally include triptorelin acetate injection, gonadorelin for injection, leuprolide acetate microspheres for injection and other drugs.
Global GnRH Agonist market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GnRH Agonist market research.
Key manufacturers engaged in the GnRH Agonist industry include Pfizer, AbbVie, AstraZeneca, Ferring, TerSera Therapeutics, Astellas Pharma, Takeda, LIVZON and Ipsen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GnRH Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GnRH Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GnRH Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
AbbVie
AstraZeneca
Ferring
TerSera Therapeutics
Astellas Pharma
Takeda
LIVZON
Ipsen
Sanofi
Endo
Tocris Bioscience
Sigma-Aldrich
MedChem Express
Arbor Pharmaceuticals
Segment by Type
Prostap
Zoladex
Triptorelin
Histrelin
Nafarelin
Others
Segment by Application
For Human
For Veterinary
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GnRH Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 GnRH Agonist Market Overview
1.1 Product Overview and Scope of GnRH Agonist
1.2 GnRH Agonist Segment by Type
1.2.1 Global GnRH Agonist Market Value Comparison by Type (2023-2029)
1.2.2 Prostap
1.2.3 Zoladex
1.2.4 Triptorelin
1.2.5 Histrelin
1.2.6 Nafarelin
1.2.7 Others
1.3 GnRH Agonist Segment by Application
1.3.1 Global GnRH Agonist Market Value by Application: (2023-2029)
1.3.2 For Human
1.3.3 For Veterinary
1.4 Global GnRH Agonist Market Size Estimates and Forecasts
1.4.1 Global GnRH Agonist Revenue 2018-2029
1.4.2 Global GnRH Agonist Sales 2018-2029
1.4.3 Global GnRH Agonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GnRH Agonist Market Competition by Manufacturers
2.1 Global GnRH Agonist Sales Market Share by Manufacturers (2018-2023)
2.2 Global GnRH Agonist Revenue Market Share by Manufacturers (2018-2023)
2.3 Global GnRH Agonist Average Price by Manufacturers (2018-2023)
2.4 Global GnRH Agonist Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of GnRH Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GnRH Agonist, Product Type & Application
2.7 GnRH Agonist Market Competitive Situation and Trends
2.7.1 GnRH Agonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest GnRH Agonist Players Market Share by Revenue
2.7.3 Global GnRH Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GnRH Agonist Retrospective Market Scenario by Region
3.1 Global GnRH Agonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global GnRH Agonist Global GnRH Agonist Sales by Region: 2018-2029
3.2.1 Global GnRH Agonist Sales by Region: 2018-2023
3.2.2 Global GnRH Agonist Sales by Region: 2024-2029
3.3 Global GnRH Agonist Global GnRH Agonist Revenue by Region: 2018-2029
3.3.1 Global GnRH Agonist Revenue by Region: 2018-2023
3.3.2 Global GnRH Agonist Revenue by Region: 2024-2029
3.4 North America GnRH Agonist Market Facts & Figures by Country
3.4.1 North America GnRH Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America GnRH Agonist Sales by Country (2018-2029)
3.4.3 North America GnRH Agonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe GnRH Agonist Market Facts & Figures by Country
3.5.1 Europe GnRH Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe GnRH Agonist Sales by Country (2018-2029)
3.5.3 Europe GnRH Agonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GnRH Agonist Market Facts & Figures by Country
3.6.1 Asia Pacific GnRH Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific GnRH Agonist Sales by Country (2018-2029)
3.6.3 Asia Pacific GnRH Agonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GnRH Agonist Market Facts & Figures by Country
3.7.1 Latin America GnRH Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America GnRH Agonist Sales by Country (2018-2029)
3.7.3 Latin America GnRH Agonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GnRH Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa GnRH Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa GnRH Agonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa GnRH Agonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GnRH Agonist Sales by Type (2018-2029)
4.1.1 Global GnRH Agonist Sales by Type (2018-2023)
4.1.2 Global GnRH Agonist Sales by Type (2024-2029)
4.1.3 Global GnRH Agonist Sales Market Share by Type (2018-2029)
4.2 Global GnRH Agonist Revenue by Type (2018-2029)
4.2.1 Global GnRH Agonist Revenue by Type (2018-2023)
4.2.2 Global GnRH Agonist Revenue by Type (2024-2029)
4.2.3 Global GnRH Agonist Revenue Market Share by Type (2018-2029)
4.3 Global GnRH Agonist Price by Type (2018-2029)
5 Segment by Application
5.1 Global GnRH Agonist Sales by Application (2018-2029)
5.1.1 Global GnRH Agonist Sales by Application (2018-2023)
5.1.2 Global GnRH Agonist Sales by Application (2024-2029)
5.1.3 Global GnRH Agonist Sales Market Share by Application (2018-2029)
5.2 Global GnRH Agonist Revenue by Application (2018-2029)
5.2.1 Global GnRH Agonist Revenue by Application (2018-2023)
5.2.2 Global GnRH Agonist Revenue by Application (2024-2029)
5.2.3 Global GnRH Agonist Revenue Market Share by Application (2018-2029)
5.3 Global GnRH Agonist Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer GnRH Agonist Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie GnRH Agonist Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AstraZeneca GnRH Agonist Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Ferring
6.4.1 Ferring Corporation Information
6.4.2 Ferring Description and Business Overview
6.4.3 Ferring GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ferring GnRH Agonist Product Portfolio
6.4.5 Ferring Recent Developments/Updates
6.5 TerSera Therapeutics
6.5.1 TerSera Therapeutics Corporation Information
6.5.2 TerSera Therapeutics Description and Business Overview
6.5.3 TerSera Therapeutics GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.5.4 TerSera Therapeutics GnRH Agonist Product Portfolio
6.5.5 TerSera Therapeutics Recent Developments/Updates
6.6 Astellas Pharma
6.6.1 Astellas Pharma Corporation Information
6.6.2 Astellas Pharma Description and Business Overview
6.6.3 Astellas Pharma GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Astellas Pharma GnRH Agonist Product Portfolio
6.6.5 Astellas Pharma Recent Developments/Updates
6.7 Takeda
6.6.1 Takeda Corporation Information
6.6.2 Takeda Description and Business Overview
6.6.3 Takeda GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Takeda GnRH Agonist Product Portfolio
6.7.5 Takeda Recent Developments/Updates
6.8 LIVZON
6.8.1 LIVZON Corporation Information
6.8.2 LIVZON Description and Business Overview
6.8.3 LIVZON GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.8.4 LIVZON GnRH Agonist Product Portfolio
6.8.5 LIVZON Recent Developments/Updates
6.9 Ipsen
6.9.1 Ipsen Corporation Information
6.9.2 Ipsen Description and Business Overview
6.9.3 Ipsen GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Ipsen GnRH Agonist Product Portfolio
6.9.5 Ipsen Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sanofi GnRH Agonist Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 Endo
6.11.1 Endo Corporation Information
6.11.2 Endo GnRH Agonist Description and Business Overview
6.11.3 Endo GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Endo GnRH Agonist Product Portfolio
6.11.5 Endo Recent Developments/Updates
6.12 Tocris Bioscience
6.12.1 Tocris Bioscience Corporation Information
6.12.2 Tocris Bioscience GnRH Agonist Description and Business Overview
6.12.3 Tocris Bioscience GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Tocris Bioscience GnRH Agonist Product Portfolio
6.12.5 Tocris Bioscience Recent Developments/Updates
6.13 Sigma-Aldrich
6.13.1 Sigma-Aldrich Corporation Information
6.13.2 Sigma-Aldrich GnRH Agonist Description and Business Overview
6.13.3 Sigma-Aldrich GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Sigma-Aldrich GnRH Agonist Product Portfolio
6.13.5 Sigma-Aldrich Recent Developments/Updates
6.14 MedChem Express
6.14.1 MedChem Express Corporation Information
6.14.2 MedChem Express GnRH Agonist Description and Business Overview
6.14.3 MedChem Express GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.14.4 MedChem Express GnRH Agonist Product Portfolio
6.14.5 MedChem Express Recent Developments/Updates
6.15 Arbor Pharmaceuticals
6.15.1 Arbor Pharmaceuticals Corporation Information
6.15.2 Arbor Pharmaceuticals GnRH Agonist Description and Business Overview
6.15.3 Arbor Pharmaceuticals GnRH Agonist Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Arbor Pharmaceuticals GnRH Agonist Product Portfolio
6.15.5 Arbor Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GnRH Agonist Industry Chain Analysis
7.2 GnRH Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GnRH Agonist Production Mode & Process
7.4 GnRH Agonist Sales and Marketing
7.4.1 GnRH Agonist Sales Channels
7.4.2 GnRH Agonist Distributors
7.5 GnRH Agonist Customers
8 GnRH Agonist Market Dynamics
8.1 GnRH Agonist Industry Trends
8.2 GnRH Agonist Market Drivers
8.3 GnRH Agonist Market Challenges
8.4 GnRH Agonist Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
